Newsroom
Novavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Novavax to Participate in Jefferies London Healthcare Conference
Novavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Perspectives & Insights
Explore our blog for valuable insights and inspiring stories from our team as we fulfill our vision to spark transformation in global health.
In the News
See what others are saying about Novavax.
Pink Sheet
The vaccine maker’s three-year transformation from commercial company to lean platform player is firmly on track.
MedCity News
Novavax Sees Sanofi Vaccine Pact as Model for Future Deals, Some Going Beyond Infectious Disease
Contagion Live
Novavax COVID-19 Vaccine Linked to Fewer Side Effects in Health Care Workers and First Responders
Note: This section features articles written by external media outlets and journalists.
About Novavax
We tackle some of the world's most significant health challenges by leveraging our scientific expertise in vaccines and cutting-edge technology platform, including protein-based nanoparticles and Matrix-M® adjuvant.
